Tat-Beclin-1

Preclinical only Anti-Aging & Longevity 2 sources

Tat-Beclin-1 is a cell-penetrating peptide that potently induces autophagy, the body's cellular recycling process. Research in animal models demonstrates its ability to clear cellular debris, combat infectious diseases, and potentially increase lifespan by promoting cellular health.

01Dosing reference

Amount

1-5 mg/kg (in animal models)

Frequency

Varies by study design (often daily or every other day in acute models)

Cycle

Short-term acute administration in preclinical settings; no established human cycle

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Cellular Penetration

The HIV-1 Tat sequence allows the peptide to easily cross cell membranes and enter the cytoplasm.

GAPR-1 Binding

Once inside, it binds to GAPR-1 (GLIPR2), a negative regulator of autophagy located on the Golgi apparatus.

Autophagy Induction

This binding releases endogenous Beclin 1, triggering the formation of autophagosomes that engulf and degrade cellular waste, misfolded proteins, and intracellular pathogens.

03Human evidence

Lack of clinical trials

Currently, there are no published human clinical trials evaluating the safety or efficacy of Tat-Beclin-1 in humans; all data is derived from cell cultures and animal models.

04Preclinical evidence

Clearance of intracellular pathogens

In mouse models, Tat-Beclin-1 administration significantly reduced mortality from infections by clearing viruses (like Chikungunya and West Nile) and bacteria (like Listeria) via enhanced autophagy.

Reduction of neurodegenerative protein aggregates

In vitro and in vivo studies show the peptide can clear polyglutamine expansion protein aggregates, suggesting potential therapeutic applications for diseases like Huntington's.

05What is known vs. unknown

Reasonably established

Potent inducer of autophagy across various mammalian cell types.
Demonstrates broad-spectrum antimicrobial activity in preclinical models by promoting the degradation of intracellular pathogens.
Shows potential in clearing misfolded proteins associated with neurodegenerative diseases.
May offer longevity benefits by enhancing cellular maintenance and waste clearance.

Unknowns & limits

Long-term safety and potential off-target effects of sustained autophagy induction in humans are unknown.
Optimal dosing, half-life, and bioavailability in human subjects have not been established.
Potential risks of excessive autophagy, which could theoretically lead to cell death or exacerbate certain conditions, require further investigation.

06Safety & regulatory context

Regulatory statusTat-Beclin-1 is strictly an experimental research chemical and is not approved by the FDA or any regulatory body for human use. Because it has not undergone human clinical trials, its safety profile, potential side effects, and contraindications are unknown. In theory, excessive induction of autophagy could lead to autophagic cell death or interfere with normal cellular processes. It is intended solely for in vitro and animal research.

07Compared with MOTS-c

Tat-Beclin-1 vs. MOTS-c

Key difference

While both are researched for longevity and cellular health, Tat-Beclin-1 specifically targets the autophagy pathway via Beclin 1, whereas MOTS-c primarily targets mitochondrial function and metabolic regulation.

When researchers discuss each

Researchers discuss Tat-Beclin-1 when focusing on cellular recycling, pathogen clearance, and protein aggregate removal, and MOTS-c when addressing metabolic dysfunction, insulin resistance, and mitochondrial optimization.

08Glossary

Autophagy

A natural cellular process that degrades and recycles damaged organelles, misfolded proteins, and intracellular pathogens.

Beclin 1

A key protein in mammals that plays a central role in the initiation of autophagy.

Cell-penetrating peptide (CPP)

A short peptide sequence (like the Tat sequence) that facilitates the transport of molecules across cell membranes.

09Knowledge check

Q1What is the primary cellular process induced by Tat-Beclin-1?

Q2What role does the 'Tat' portion of Tat-Beclin-1 serve?

Q3Which statement best reflects a documented limitation of the Tat‑Beclin‑1 evidence in the dossier?

Q4When researchers contrast Tat‑Beclin‑1 with MOTS‑c, Tat‑Beclin‑1 is primarily discussed in the context of which research focus?

Q5Which statement accurately describes the regulatory and safety context for Tat‑Beclin‑1 as given in the dossier?

10Sources

More in Anti-Aging & Longevity

See all

Epitalon

Anti-Aging & Longevity

Human clinical

Epitalon is a synthetic tetrapeptide designed to mimic the effects of epithalamin, a natural polypeptide produced in the pineal gland. Research suggests it can activate telomerase, elongate telomeres, regulate melatonin production, and potentially extend lifespan in animal models.

5-10 mg/day

SS-31 (Elamipretide)

Anti-Aging & Longevity

Human clinical

SS-31, also known as elamipretide, is a mitochondria-targeted peptide that binds to cardiolipin in the inner mitochondrial membrane. It helps restore mitochondrial function, reduce oxidative stress, and improve cellular energy production. Research has heavily focused on its potential for treating heart failure, mitochondrial myopathies, and age-related cellular decline.

2-4 mg/day

FOXO4-DRI

Anti-Aging & Longevity

Preclinical only

FOXO4-DRI is an engineered peptide designed to selectively induce apoptosis (programmed cell death) in senescent cells. Research in animal models suggests it can clear these 'zombie cells' by disrupting the interaction between the FOXO4 and p53 proteins, potentially reversing signs of aging and restoring tissue function.

1-3 mg/day (theoretical research dose)

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.